Risk, I'm still trying to piece it all together, but from what I can tell Dr. Urano was a visiting professor at UMass for a short period of time (last couple of years) during which he submitted the patent application that we've all seen now. I saw some material on his Facebook page which showed him at a farewell dinner thrown by his colleagues and students at UMass, so it appears that he's now back at his home university (Wash U in St. Louis). It's not that unusual for professors of this caliber to accept temporary research positions at other schools, and it appears to me that's what happened here. It would seem that his work on Wolfram and diabetes research is continuing where he is now.
A lot going on with MANF and Diabetes. Let's not forget about the grant for research going on in Helsinki for Diabetes. Looks like PD might be on the back burner and Diabetes is taking priority.
Gerald might have perked up not because of a personal interest but because your comment about not being able to do a clinical study was 100% wrong and he wanted to explain to you that it if AMBS can get MANF orphan status for Wolfram's that a clinical trial will absolutely happen. Rare diseases like this always have a database of who has it. The ability to assemble willing participants won't be a problem, imho. The biggest problem AMBS will have is thge $$$ to do so. So here's hoping that AMBS can find a partner to help it get MANF into as many clinical trials as possible.
Market Data 
Markets 
AI
